Stephen J. Kron to Antineoplastic Agents
This is a "connection" page, showing publications Stephen J. Kron has written about Antineoplastic Agents.
Connection Strength
0.727
-
Small-molecule drug repurposing to target DNA damage repair and response pathways. Semin Cancer Biol. 2021 01; 68:230-241.
Score: 0.313
-
A bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells. Mol Cancer Ther. 2010 May; 9(5):1469-81.
Score: 0.158
-
Targeted Covalent Inhibition of Telomerase. ACS Chem Biol. 2020 03 20; 15(3):706-717.
Score: 0.078
-
Nanoparticle formulations of cisplatin for cancer therapy. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 09; 8(5):776-91.
Score: 0.059
-
Activity assay of epidermal growth factor receptor tyrosine kinase inhibitors in triple-negative breast cancer cells using peptide-conjugated magnetic beads. Assay Drug Dev Technol. 2013 Feb; 11(1):44-51.
Score: 0.047
-
gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006 May; 6(3):197-205.
Score: 0.030
-
Quinic Acid-Conjugated Nanoparticles Enhance Drug Delivery to Solid Tumors via Interactions with Endothelial Selectins. Small. 2018 12; 14(50):e1803601.
Score: 0.018
-
Mps1 Mediated Phosphorylation of Hsp90 Confers Renal Cell Carcinoma Sensitivity and Selectivity to Hsp90 Inhibitors. Cell Rep. 2016 Feb 02; 14(4):872-884.
Score: 0.015
-
Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array. Biosens Bioelectron. 2010 Oct 15; 26(2):424-31.
Score: 0.010